Inflammation and Pancreatic Cancer: Recent Development with Focusing on Potential New Drug Targets

Author(s): Generoso Uomo, Luigi Laghi, Raffaele Pezzilli

Journal Name: Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents

Volume 10 , Issue 5 , 2011

Become EABM
Become Reviewer
Call for Editor


Chronic inflammation has been identified as a significant factor in the carcinogenesis of various tumors, including pancreatic cancer. Both hereditary and classical forms of chronic pancreatitis are associated with an increased risk of developing pancreatic cancer. Cytokines and other mediators of the inflammatory process together with an upregulation of pro-inflammatory pathways play a pivotal role in oncogenesis stimulation, tumor growth and metastasis. The presence of a strong desmoplastic reaction within and around pancreatic cancer cells renders the proteolytic degradation of extracellular matrix components an essential process for tumor invasion and metastasis. Various classes of proteases produced by the pancreatic acinar cells are involved in these proteolytic events. The multiple link between inflammation and pancreatic cancer may represent the basis for a novel antineoplastic strategy. Cytokines, proteases, reactive-oxygen-species, cyclooxygenase-2, nuclear-factor-κB and perixosome proliferator-activated receptor-γ may be a new molecular targets useful for therapeutic purpose.

Keywords: Cyclooxygenase-2, cytokines, gabexate mesilate, nuclear-factor-kappaB, pancreatic neoplasms, pancreatitis, chronic, perixosome proliferator-activated receptor-gamma, proteases, reactive oxygen species, stromal cells

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [351 - 357]
Pages: 7
DOI: 10.2174/1871523011109050351
Price: $65

Article Metrics

PDF: 16